It is anticipated that non-invasive throat swabs, which contain a high number of viral particles during an infection , would be utilised when stratifying individuals that are positive or negative for target enteroviral nucleic acid, using gold-aptamer nanoconstructs. Therefore, to determine the applicability of the gold-aptamer-nanoconstructs in the real-world scenario of a typical doctor-patient consultation, preliminary experiments were conducted to determine the lateral flow assay efficacy, at its detection limit, with equivalent concentrations of human genomic DNA (1x10 -7 M). In the absence of conserved target enteroviral nucleic acid (1x10 - 7 ) the assay is negative, since human genomic DNA does not initiate the signal transduction pathway (Figure ). Furthermore, in the presence of conserved target enteroviral nucleic acid the human genomic DNA did not affect the sensitivity of the lateral flow assay.